

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

<https://marketpublishers.com/r/V6FDB9BA5E06EN.html>

Date: July 2020

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: V6FDB9BA5E06EN

Abstracts

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020'; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 16 molecules.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

The report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020' outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 5, 6, 3 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR) and Uveal

Melanoma.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects

The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies
Involved in Therapeutics Development

Alteogen Inc

Amgen Inc

Cinnagen Co

Clover Biopharmaceuticals

Coherus BioSciences Inc

CSL Ltd

Formycon AG

Gene Techno Science Co Ltd

Huons Global Co Ltd

Luye Pharma Group Ltd

Momenta Pharmaceuticals Inc

PharmAbcine Inc

Regeneron Pharmaceuticals Inc

Sam Chun Dang Pharm Co Ltd

Samsung Bioepis Co Ltd

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Alteogen Inc, H2 2020

Pipeline by Amgen Inc, H2 2020

Pipeline by Cinnagen Co, H2 2020

Pipeline by Clover Biopharmaceuticals, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Alteogen Inc

Amgen Inc

Cinnagen Co

Clover Biopharmaceuticals

Coherus BioSciences Inc

CSL Ltd

Formycon AG

Gene Techno Science Co Ltd

Huons Global Co Ltd

Luye Pharma Group Ltd

Momenta Pharmaceuticals Inc

PharmAbcine Inc

Regeneron Pharmaceuticals Inc

Sam Chun Dang Pharm Co Ltd

Samsung Bioepis Co Ltd

I would like to order

Product name: Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/V6FDB9BA5E06EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V6FDB9BA5E06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970